Sandoz (SDZNY), Friday said that it has launched a generic formulation of paclitaxel in the US, the first generic to its reference medicine Abraxane, a nanoparticle formulation of paclitaxel, to be approved by the US Food and Drug Administration (FDA).
Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of patients with metastatic breast cancer.
The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on October 8, 2024.
Abraxane is sold by Abraxis BioScience, a Bristol-Myers Squibb company.
For comments and feedback: editorial@rttnews.com